re in the reproductive age group, Tamoxifen is still your primary option for hormonal treatment. For post-menopausal women who have breast cancer, and are
estrogen receptor (ER) or progesterone receptor (PR) positive, switching from Tamoxifen to Aromasin would confer an advantage in terms of reducing the risk of cancer recurrence.
The most common side effects associated with Tamoxifen are hot flashes, vaginal dryness, nausea and weight gain.